A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
Safinamide is an approved drug for the treatment of motor fluctuations in Parkinson’s disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios...
Main Authors: | Javier Pagonabarraga, José Matías Arbelo, Francisco Grandas, Maria-Rosario Luquin, Pablo Martínez Martín, Mari Cruz Rodríguez-Oroz, Francesc Valldeoriola, Jaime Kulisevsky |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3425/10/3/176 |
Similar Items
-
Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
by: Gloria Martí-Andrés, et al.
Published: (2019-10-01) -
Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
by: Bette S, et al.
Published: (2018-09-01) -
Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
by: Stocchi F, et al.
Published: (2016-02-01) -
SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
by: Ana Gómez-López, et al.
Published: (2021-01-01) -
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson’s Disease
by: Abbruzzese G, et al.
Published: (2021-06-01)